Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive on Monday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AbbVie earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.3167249716419 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- BRIEF-AbbVie Says CEO’s 2017 Total Compensations Were $22.63 Mln Vs $20.97 Mln In 2016 (feeds.reuters.com)
- Stocks News Update: Zynga, Inc. (NASDAQ:ZNGA), AbbVie Inc. (NYSE:ABBV) – The Oracle Examiner (oracleexaminer.com)
- Day Traders Must Read Before Invest – AbbVie Inc (NYSE: ABBV) – Alpha Beta Stock (alphabetastock.com)
- J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit (finance.yahoo.com)
- Recurrent Malignant Glioma – Pipeline Review: Global Market Outlook & Research study by Key Players (AbbVie Inc … – Healthcare Journal (journalhealthcare.com)
A number of research analysts have weighed in on ABBV shares. Societe Generale raised their price objective on AbbVie in a report on Tuesday, November 21st. SunTrust Banks raised their price objective on AbbVie to $157.00 and gave the company an “average” rating in a report on Monday, January 29th. Jefferies Group raised their target price on AbbVie from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of AbbVie in a research note on Tuesday, January 2nd. Finally, Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $120.96.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion during the quarter, compared to analysts’ expectations of $7.53 billion. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.20 EPS. sell-side analysts anticipate that AbbVie will post 7.48 EPS for the current fiscal year.
AbbVie declared that its Board of Directors has initiated a stock repurchase plan on Thursday, February 15th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be paid a $0.96 dividend. This represents a $3.84 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Thursday, April 12th. This is a boost from AbbVie’s previous quarterly dividend of $0.71. AbbVie’s dividend payout ratio (DPR) is presently 86.32%.
In related news, CFO William J. Chase sold 70,928 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $117.18, for a total transaction of $8,311,343.04. Following the completion of the sale, the chief financial officer now owns 203,391 shares in the company, valued at $23,833,357.38. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Carlos Alban sold 83,574 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $114.49, for a total value of $9,568,387.26. Following the sale, the executive vice president now owns 133,026 shares of the company’s stock, valued at approximately $15,230,146.74. The disclosure for this sale can be found here. Insiders sold a total of 211,197 shares of company stock valued at $24,585,575 in the last quarter. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/19/abbvie-abbv-getting-somewhat-positive-media-coverage-analysis-finds/2019934.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.